NCT07607964
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
Version history last read from ClinicalTrials.gov on Oct 21, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.
All 15 versions: 13 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 13 → 17 locations
- Minor Study sites: 14 to 15
- Minor Study sites: 13 to 14
- Minor Study sites: 12 to 13
- Minor Study sites: 11 to 12
Show 4 earlier versionsHide 4 earlier versions
- Notable Eligibility criteria expanded, about 15 words
- Primary endpoints: details revised at 1 of 7 entries
- Study sites: 10 to 11
- Minor Study sites: 9 to 10v9
- Minor Study sites: 10 to 9v8
- Minor Study sites: 9 to 10v7
- Minor Trial sites expanded: 6 → 9 locationsv6
- Minor Study sites: 5 to 6v5
- Notable Recruitment opened
- Study sites: 4 to 5
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 3 to 4
- Start date changed from estimate of May 29, 2026 to May 28, 2026
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Arms and interventions
Participants will receive a single intravenous (IV) dose of ABBV-519
Participants will receive a single intravenous (IV) dose of ABBV-519
Participants will receive a single intravenous (IV) dose of ABBV-519
Participants will receive a single subcutaneous (SC) dose of ABBV-519
Participants will receive a single subcutaneous (SC) dose of ABBV-519
Drugs: ABBV-519
Sites
17 sites in 2 countries
United States 12, Japan 5